El interés en corto de Assembly Biosciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Assembly Biosciences. Los datos de interés en corto se actualizan cada dos semanas.

Assembly Biosciences (NASDAQ:ASMB) Bolsa, Informe de interés en corto

Assembly Biosciences

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences Inc

In October 2024, the Company completed its previous one-year&nbsp;$75 million&nbsp;share repurchase program.

News

Buybacks

Minerals Technologies Board Authorizes New $200M Share Repurchase Program

The dividend is payable on&nbsp;December 5, 2024, to stockholders of record at the close of business on&nbsp;October 31, 2024.

Dividends

Minerals Technologies Boosts Regular Quarterly Dividend By 10% From $0.10 To $0.11 Per Share

Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) has outperformed the market over the past 5 years by 3.86% on an annualized basis producing an average annual return of 18.12%. Currently, Cleanspark has a market capitalization of $3.03 billion. 
Buying $100 In CLSK: If an investor had bought $100 of CLSK stock 5 years ago, it would be worth $232.16 today based on a price of $11.96 for CLSK at the time of writing.
<h3>Cleanspark's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729114272_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

CLSK

Here's How Much $100 Invested In Cleanspark 5 Years Ago Would Be Worth Today

WIIM

CENX

Century Aluminum shares are trading higher in sympathy with Alcoa, which reported better-than-expected Q3 adjusted EPS results.

Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) has outperformed the market over the past 10 years by 3.59% on an annualized basis producing an average annual return of 15.21%. Currently, Ciena has a market capitalization of $9.57 billion. 
Buying $1000 In CIEN: If an investor had bought $1000 of CIEN stock 10 years ago, it would be worth $4,281.03 today based on a price of $66.57 for CIEN at the time of writing.
<h3>Ciena's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729114267_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CIEN

Here's How Much $1000 Invested In Ciena 10 Years Ago Would Be Worth Today

DPA-1 provides for a criminal monetary penalty and forfeiture of $282 million to be paid to the DOJ within 10 business days.&nbsp;In addition, the SEC&rsquo;s administrative cease and desist order found that Raytheon violated the anti-bribery, books and records, and internal controls provisions of the FCPA. The order provides for a $102 million payment to the SEC that includes disgorgement, prejudgment interest on disgorgement, and a civil penalty to be paid within 14 calendar days.
DPA-2 provides for a criminal penalty in the amount of $147 million to be paid within 10 business days, and the FCA Settlement Agreement provides for an FCA settlement payment in the amount of $428 million, which includes restitution, plus interest, to be paid within 7 calendar days.
&nbsp;
&nbsp;

RTX Enters Deferred Prosecution Agreement With DoJ And Also Enters False Claims Act Settlement Agreement To Resolve Government Investigations Into Defective Pricing Claims - Filing

Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares are trading lower in Wednesday&#8217;s after-hours session after the company announced an offering and corresponding investment from an affiliate of the <a href="https://www.benzinga.com/pressreleases/24/10/n41368754/lucid-group-inc-announces-public-offering-of-common-stock-and-corresponding-investment-by-an-affil" target="_blank" rel="noreferrer noopener">Public Investment Fund (PIF)</a>.
What Happened: Lucid said it commenced a public offering of 262,446,931 shares of its common stock. The company intends to grant the underwriter a 30-day option to purchase up to 39,367,040 additional shares.
In connection with the offering, Lucid announced that majority shareholder and PIF affiliate Ayar Third Investment Company&nbsp;has agreed to purchase 374,717,927 shares of common stock from Lucid in a private placement. Ayar expects to maintain approximately 58.8% ownership of Lucid following the purchases.
Lucid said it will use the net proceeds from the public offering and concurrent private placement for general corporate purposes, which may include capital expenditures and working capital.
Lucid ended the second quarter with $4.28 billion&nbsp;in total liquidity, including $1.35 billion in cash and cash equivalents.
The EV maker announced the date for its <a href="https://www.benzinga.com/calendars/earnings">third-quarter earnings release</a> this week: Lucid will report quarterly results after the market close on Nov. 7. Analysts anticipate a loss of 30 cents per share and revenue of $194.981 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
LCID Price Action: <a href="http://benzinga.com/quote/lcid">Lucid shares</a> were down 10.98% in after-hours, trading at $2.92 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41348730/elon-musks-tesla-waving-goodbye-to-bitcoin-760m-sent-to-unknown-wallets">Elon Musk&#8217;s Tesla Waving Goodbye To Bitcoin? $760M Sent To Unknown Wallets</a></li>
</ul>
Photo: Courtesy of Lucid Group.

Offerings

After-Hours Center

Movers

LCID

Lucid Stock Is Tumbling Wednesday: What's Driving The Action?

Steel Dynamics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) shares are trading higher in Wednesday&#8217;s after-hours session on the heels of the company&#8217;s third-quarter financial results. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/10/n41368536/steel-dynamics-reports-third-quarter-2024-results">rundown of the print</a>.
<ul>
<li>Q3 Revenue: $4.34 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $4.177 billion</li>
</ul>
<ul>
<li>Q3 EPS: $2.05, versus estimates of $1.97</li>
</ul>
Steel Dynamics said it shipped 3.2 million tons of steel during the third quarter and generated cash flow from operations of $760 million. The company ended the quarter with $3.1 billion in liquidity.
&#8220;Underlying steel demand continued to be stable in the&nbsp;third quarter. However, earnings declined sequentially, based on lower average realized steel pricing, primarily within the flat rolled operations as generally&nbsp;80 percent&nbsp;of this business is contractually based and tied to lagging pricing indices,&#8221; said Mark Millett, co-founder, chairman and CEO of Steel Dynamics.
&#8220;Steady steel demand, coupled with continued low customer inventory and stabilized scrap prices, resulted in stabilization and improvement in flat-rolled steel prices during the later part of the third quarter. Our long product steel operations realized a slight improvement in metal spread as scrap pricing declined more than average realized pricing.&#8221;  
See Also: <a href="https://www.benzinga.com/news/earnings/24/10/41369150/discover-reports-better-than-expected-q3-results-higher-delinquency-rates-yoy-details">Discover Reports Better-Than-Expected Q3 Results, Higher Delinquency Rates YOY: Details</a>
What&#8217;s Next: Steel Dynamics said it&#8217;s &#8220;constructive&#8221; regarding the outlook for the 2025 metals market. The company expects steel prices to recover into 2025. 
&#8220;We believe current trade actions could also reduce volumes of unfairly traded steel imports into the United States, especially for coated flat-rolled steel, which could have a significant positive impact for us,&#8221; the company said.
Steel Dynamics noted it expects to realize additional earnings power in 2025 from the four new flat-rolled steel coating lines that began operating earlier this year. The company also plans to start operating its new aluminum flat-rolled mill in mid-2025.
Management will hold a conference call to discuss these results with investors and analysts Thursday morning at 11 a.m. ET.
STLD Price Action: <a href="http://benzinga.com/quote/stld">Steel Dynamics shares</a> were up 2.43% in after-hours, trading at $133.02 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: BildWerk from Shutterstock.

Guidance

Commodities

STLD

Steel Dynamics Stock Jumps On Q3 Earnings: Highlights From The Report

Robert J. Hariri, Chairman, CEO and founder of Celularity. &quot;We expect Rebound sales to contribute meaningfully in the&nbsp;fourth quarter&nbsp;2024 and to fulfill expected full year 2024 biomaterial sales which we announced in February, augmenting our other revenues from biobanking and research agreements.&quot;&nbsp;

CELU

Celularity Acquires Rebound, A Placental-derived Allograft Matrix Product, From Sequence LifeScience; No Terms Disclosed

Home BancShares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOMB#NYSE">HOMB</a>) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.53 by 5.66 percent. This is a 6.38 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $257.99 million which missed the analyst consensus estimate of $258.90 million by 0.35 percent. This is a 5.15 percent increase over sales of $245.35 million the same period last year.

Earnings

Earnings Misses

HOMB

Home BancShares Q3 2024 Adj EPS $0.50 Misses $0.53 Estimate, Sales $257.99M Miss $258.90M Estimate

The Company will continue to monitor the situation and take appropriate actions consistent with its response protocols. As of the date of this filing, the incident has not caused, and is not expected to cause, disruption of the Company&rsquo;s business operations.
And although the full nature and scope of the incident is not yet known, the Company does not believe it will have a material effect on its financial condition or results of operations.

HCSG

Healthcare Services Group Identified Cybersecurity Incident Involving Unauthorized Activity Within Some Of Its Systems; Expects No Disruption, Material Effect On Operations - Filing

Macro Economic Events

Market Summary

Economics

General

NVDA

Benzinga Market Summary: Indexes Close Higher Amid A Rebound In NVIDIA And Strength In Morgan Stanley, Alcoa Pops On Strong Q3 Earnings, Airlines Close Higher Following UAL Earnings

With power now restored, the Company has safely resumed the ramp-up of milling, flotation, and filtration circuits within the processing plant.

Ero Copper Says Full Power Restored At Its Tucumã Operation Following Temporary Disruption Caused By Severe Localized Windstorm

CSX Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) shares are trading lower after the railroad company reported its third-quarter financial results after Wednesday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/24/10/g41367454/csx-corp-announces-third-quarter-2024-results">figures from the quarter. </a>
The Details: CSX reported quarterly GAAP earnings of 46 cents per share, which missed the consensus estimate of 48 cents per share. Quarterly revenue came in at $3.62 billion, also missing the consensus estimate of $3.676 billion. The company said its total volume of 1.59 million units for the quarter was 3% higher as compared to the third quarter of 2023.
Read Next:&nbsp; <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41340022/amazon-analyst-expects-q3-earnings-with-revenue-growth-margin-expansion-relative-st">Amazon Analyst Expects Q3 Earnings With Revenue Growth, Margin Expansion, Relative Stable E-Commerce Demand</a>
&#8220;CSX&#8217;s commitment to excellent service allowed us to deliver meaningful growth in volume, operating income and operating margin in the third quarter,&#8221; said Joe Hinrichs, CEO of CSX.
&#8220;Over the last several weeks CSX, along with many of the communities in which we operate, was presented with significant challenges brought about by the recent hurricanes. Thanks to the dedication of our employees, our network has remained flexible and resilient, and we remain ready to meet our customers&#8217; needs as they increasingly favor the efficiency and reliability being delivered by the ONE CSX team,&#8221; added Hinrichs. 
CSX Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, CSX shares are down 3.95% after-hours at $34.07 at the time of publication Wednesday.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41321567/teslas-optimus-robots-were-remotely-assisted-by-humans-at-we-robot-event">Tesla&#8217;s Optimus Robots Were Remotely Assisted By Humans At &#8216;We, Robot&#8217; Event</a></li>
</ul>
Photo: Shutterstock

CSX Stock Falls After Worse-Than-Expected Q3 Results: Details

Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $62.8, a high estimate of $67.00, and a low estimate of $55.00. This current average has not changed from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1729112465_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Corteva. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$67.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$62.00</td>
<td>$66.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Corteva. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Corteva compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Corteva's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Corteva's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CTVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Corteva analyst ratings.</a>
<h2>About Corteva</h2>
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
<h3>Corteva's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Corteva showcased positive performance, achieving a revenue growth rate of 1.11% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.
Net Margin: Corteva's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.23% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Corteva's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.22%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Corteva's ROA excels beyond industry benchmarks, reaching 2.48%. This signifies efficient management of assets and strong financial health.
Debt Management: Corteva's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CTVA

Decoding 5 Analyst Evaluations For Corteva

In the latest quarter, 9 analysts provided ratings for Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Civitas Resources and provided 12-month price targets. The average target is $83.56, accompanied by a high estimate of $101.00 and a low estimate of $60.00. A 13.73% drop is evident in the current average compared to the previous average price target of $96.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1729112443_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Civitas Resources. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$81.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Zach Parham</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$67.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Civitas Resources. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Civitas Resources compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Civitas Resources's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CIVI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Civitas Resources analyst ratings.</a>
<h2>All You Need to Know About Civitas Resources</h2>
Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado (DJ Basin). The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.
<h3>Civitas Resources's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Civitas Resources's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 98.73%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Civitas Resources's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.45%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Civitas Resources's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.27%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Civitas Resources's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.43%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Civitas Resources's debt-to-equity ratio stands notably higher than the industry average, reaching 0.74. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CIVI

Unveiling 9 Analyst Insights On Civitas Resources

Providing a diverse range of perspectives from bullish to bearish, 17 analysts have published ratings on Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.32, a high estimate of $38.00, and a low estimate of $16.50. Observing a 8.92% increase, the current average has risen from the previous average price target of $21.41. 
<img src="https://www.benzinga.com/files/images/story/2024/1729112436_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Sunrun among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$23.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Corinne Blanchard</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$16.50</td>
<td>$12.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sunrun. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sunrun compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Sunrun's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sunrun's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RUN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sunrun analyst ratings.</a>
<h2>About Sunrun</h2>
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed either by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
<h3>Financial Milestones: Sunrun's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Sunrun faced challenges, resulting in a decline of approximately -11.24% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Sunrun's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 26.72% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sunrun's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.65% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Sunrun's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.66% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Sunrun's debt-to-equity ratio stands notably higher than the industry average, reaching 2.25. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Sunrun

Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) has outperformed the market over the past 15 years by 1.8% on an annualized basis producing an average annual return of 13.6%. Currently, Delta Air Lines has a market capitalization of $36.30 billion. 
Buying $1000 In DAL: If an investor had bought $1000 of DAL stock 15 years ago, it would be worth $6,759.90 today based on a price of $56.26 for DAL at the time of writing.
<h3>Delta Air Lines's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729112429_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Delta Air Lines 15 Years Ago Would Be Worth This Much Today

In the latest quarter, 14 analysts provided ratings for Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Antero Resources, presenting an average target of $32.93, a high estimate of $44.00, and a low estimate of $25.00. This current average has decreased by 7.24% from the previous average price target of $35.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1729112426_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Antero Resources. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>Walter Pritchard</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$34.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$25.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Paul Diamond</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Doug Leggate</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$32.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Leo Mariani</td>
<td>Roth MKM</td>
<td>Announces</td>
<td>Buy</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Cameron Bean</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$44.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Antero Resources. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Antero Resources compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Antero Resources's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Antero Resources's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Antero Resources analyst ratings.</a>
<h2>About Antero Resources</h2>
Antero Resources, based in Denver, engages in the exploration for and production of natural gas and natural gas liquids in the United States and Canada. At the end of 2023, the company reported proven reserves of 18.1 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,483 million cubic feet of equivalent a day in 2023 at a ratio of 37% liquids and 63% natural gas.
<h3>Breaking Down Antero Resources's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Antero Resources showcased positive performance, achieving a revenue growth rate of 3.86% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Antero Resources's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -7.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Antero Resources's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.94%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Antero Resources's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.49%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.63, Antero Resources faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

14 Analysts Assess Antero Resources: What You Need To Know

Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) has outperformed the market over the past 5 years by 7.36% on an annualized basis producing an average annual return of 21.62%. Currently, Alphabet has a market capitalization of $2.03 trillion. 
Buying $100 In GOOGL: If an investor had bought $100 of GOOGL stock 5 years ago, it would be worth $265.47 today based on a price of $165.24 for GOOGL at the time of writing.
<h3>Alphabet's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729112425_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GOOGL

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Assembly Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/asmb-stock-quote/">ASMB</a>) just reported results for the first quarter of 2024.<ul><li>Assembly Biosciences reported earnings per share of -$1.66. This was above the analyst estimate for EPS of -$3.24.</li><li>The company reported revenue of $5.79 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/asmb-stock-earnings-assembly-biosciences-for-q1-of-2024/">ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q1 2024

Assembly Biosciences (ASMB) has provided an announcement. At Assembly Biosciences, Inc.'s 2024 Annual Meeting, stockholders passed key resolutions,...

Assembly Biosciences Enhances Stock Plans and Elects Board

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Assembly Biosciences (ASMB – Research Report) today. The company's shares closed yester...

H.C. Wainwright Sticks to Their Hold Rating for Assembly Biosciences (ASMB)

Assembly Biosciences closes $12.6M in equity financings

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Assembly Biosciences (ASMB – Research Report). The company's s...

H.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)

Assembly Biosciences GAAP EPS of -$1.98 beats by $0.25

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Assembly Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/asmb-stock-quote/">ASMB</a>) just reported results for the second quarter of 2024.<ul><li>Assembly Biosciences reported earnings per share of -$1.98. This was above the analyst estimate for EPS of -$2.23.</li><li>The company reported revenue of $8.53 million.</li><li>This was 43.17% better than the analyst estimate for revenue of $5.96 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/asmb-stock-earnings-assembly-biosciences-for-q2-of-2024/">ASMB Stock Earnings: Assembly Biosciences Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ASMB Stock Earnings: Assembly Biosciences Beats EPS, Beats Revenue for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Thermo Fisher (TMO – Research Report), Nyxoah (NYXH ...

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Nyxoah (NYXH) and Assembly Biosciences (ASMB)

Capitulation in biotech is near, as well as a rally – Piper Sandler

ASMB

CDNA

DTIL

EXEL

IBBQ

IDNA

NTRA

NYXH

PRAX

PTGX

SPRY

TRDA

Biotech

Press Releases

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Health Care

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

Assembly Biosciences Announces $12.6 Million in Equity Financings

Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366

Comments

Assembly Biosciences

Interés en corto

Assembly Biosciences (NASDAQ:ASMB) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL